China is among the top countries reporting a high number of diagnosed prevalent cases for gastric, breast, and bladder cancers among the 16 major markets
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Proposed combination enhances Pfizer’s position as a leading company in oncology
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates
Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
DEP® ADCs exploit the unique potential of Starpharma's DEP® technology to provide enhanced characteristics to ADCs i
All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
This new €59 million, 70,000 square foot facility, officially opened today, brings 50 new jobs to the area
Subscribe To Our Newsletter & Stay Updated
